1.Targeted Treatment for Advanced Solid Tumors (Posted: 12/16/2008) - This clinical trial combines the drug dasatinib with the angiogenesis inhibitor bevacizumab for patients with metastatic or unresectable solid tumors. 2.New Drug for Patients with Metastatic or Inoperable Kidney Cancer (Posted: 09/23/2008) - In this randomized trial, patients who have kidney cancer that cannot be surgically removed (unresectable) or that has spread (metastatic) and who have previously received sorafenib or sunitinib will take vandetanib daily until their disease progresses or they develop unacceptable side effects. 3.Targeted Combinations for Metastatic Kidney Cancer (Posted: 11/06/2007) - In this trial, doctors are testing different combinations of the molecularly targeted agents bevacizumab, sorafenib, and temsirolimus in patients with metastatic kidney cancer. 4.Biological Therapy for Advanced Kidney Cancer or Melanoma (Posted: 07/10/2007) - This phase I clinical trial will assess the safety and tolerability of a new biological agent called GC1008 in patients with advanced kidney cancer or melanoma. 5.Gene Therapy for Metastatic Cancer (Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients.
